US FDA approves Lantheus’ new prostate cancer imaging formulation
ReutersMar 6, 2026 9:03 PM
March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings’ LNTH.O prostate cancer imaging agent, aimed at improving scanning access through increased production capacity.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Is the Market No Longer ‘Buying Asia’? Why Asian Stocks Face Selloff Amid US-Iran Conflict While US Stocks Become a Safe Haven?
Has the "Sell US, Buy Asia" trade, once prevalent at the beginning of the year, now become obsolete? Will the U.S.-Iran conflict fundamentally reverse the robust 2026 rally in emerging markets?TradingKey
2 hours ago
Is the Market No Longer ‘Buying Asia’? Why Asian Stocks Face Selloff Amid US-Iran Conflict While US Stocks Become a Safe Haven?
Has the "Sell US, Buy Asia" trade, once prevalent at the beginning of the year, now become obsolete? Will the U.S.-Iran conflict fundamentally reverse the robust 2026 rally in emerging markets?TradingKey
2 hours ago
Investing in GameStop 2026: Holding Company Transformation or Just More Hype?
Although GameStop still has physical stores, it is predominantly looking to buy/build out new businesses that can expand more quickly than it is shrinking traditional video game retail stores, which are going to disappear.TradingKey
12 hours ago
It’s Not Gold Soaring; It’s Paper Money Shrinking: Measuring Gold with Five Real-World Yardsticks
TradingKey – Want to know where gold’s true level really is? This article measures it against stocks, the US dollar, housing, oil and even burgers to show where its price really stands today.TradingKey
19 hours ago
Is the MSTR Bubble Bursting? Assessing Strategy’s BTC Holdings Amid Massive Share Dilution
Is the MSTR bubble bursting? Explore Strategy’s high-stakes 720,000 BTC treasury as of March 2026. This analysis breaks down the 42/42 funding strategy, the shift to STRC preferred shares, and the impact of mass equity dilution on the Bitcoin Yield KPI. Learn how MSCI index inclusion and record shorTradingKey
Thu, Mar 5
